- Yaro on AI and Tech Trends
- Posts
- AI Unleashed š¤ How Far Could It Go?
AI Unleashed š¤ How Far Could It Go?
Are Tech-Driven Personalized Medicine Boosting GLP-1 Drugs?
Get in Front of 50k Tech Leaders: Grow With Us
If you'd like to unsubscribe, please look at the link at the bottom of this email.
Is the New Administration Unleashing AI? What This Means for Us. How might this shape the next generation of AI models ā making them better or perhaps even more unsettling? Letās discuss. Meanwhile, advancements in personalized medicine are accelerating, driven by technology, yet more data is essential. Letās dive in, team!
What Did the Leak of OpenAI's Next ChatGPT Model Reveal?
Are Tech-Driven Personalized Medicine Boosting GLP-1 Drugs?
AI Unleashed ā How Far Could It Go?
š§° AI Tools (Phone Calls)
š° News and Trends.
Discover 100 Game-Changing Side Hustles for 2024
In today's economy, relying on a single income stream isn't enough. Our expertly curated database gives you everything you need to launch your perfect side hustle.
Explore vetted opportunities requiring minimal startup costs
Get detailed breakdowns of required skills and time investment
Compare potential earnings across different industries
Access step-by-step launch guides for each opportunity
Find side hustles that match your current skills
Ready to transform your income?
What Did the Leak of OpenAI's Next ChatGPT Model Reveal?
OpenAIās o1 model, expected to launch this year, was briefly accessible due to an unintentional leak, showcasing impressive capabilities. Unlike previous models, o1 can "reason" through problems more slowly, significantly enhancing accuracy. A preview version, o1-preview, hinted at these improvements, but the leaked full version demonstrated even more, including advanced image analysis.
Users found it could solve complex image puzzles, spending minutes analyzing details such as colors and motion in a SpaceX rocket launch photo. This release diverges from standard GPT models and could revolutionize multimedia reasoning in AI. OpenAI hasnāt confirmed a full release date but is expected to unveil it after the U.S. Presidential election.
Our Partners:
OpenVC University - Jumpstart your AI career in 100 days with OpenCV Universityās AI Challenge ā master AI, Computer Vision, and Deep Learning with a 35% discount!
FRENZ Brainband by Earable - Silence your thoughts and drift into a deeper sleep. āAI-powered, scientifically-backed sleep tech transforming restless nights into restful slumber. Exclusive savings with code 'celis'!*
UPDF! - Unlock powerful PDF editing and secure your documents with UPDF ā edit, sign, convert, and more on any device!
Are Tech-Driven Personalized Medicine Boosting GLP-1 Drugs?
Novo Nordiskās Wegovy achieved a 79% sales boost, outperforming expectations and calming investors after Eli Lillyās obesity drug fell short. In the U.S., Wegovyās sales rose 50% as more insurers covered the drug, lifting Novo Nordiskās stock by nearly 9%, though concerns remain about sustaining growth.
Ozempic and Wegovy, both GLP-1 drugs, add to the advances personalized medicine, and similar treatments which are part of a new generation of drugs that address obesity by mimicking natural appetite-regulating hormones. Technology is accelerating personalized medicine in this space, with AI, genetic profiling, and health data enabling precise targeting of patient needs and responses. This tech-driven approach enhances drug efficacy and market reach, making GLP-1 therapies increasingly accessible and effective for metabolic health.
š§° AI Tools
Phone Calls
AICaller.io - AICaller is a simple-to-use automated bulk calling solution that uses the latest Generative AI technology to trigger phone calls for you and get things done. It can do things like lead qualification, data gathering over phone calls, and much more. It comes with a powerful API, low cost pricing and free trial.
Cald.ai - AI based calling agents for outbound and inbound phone calls.
Rosie - AI Phone Answering Service
Download over 750+ Tools free here.
AI Unleashed ā How Far Could It Go?
The recent Republican victory suggests a shift toward a more permissive approach to AI, moving away from the Biden administration's regulatory caution. The new administration tech policy will emphasize deregulation, with a focus on competing with China and avoiding burdensome safety measures.
This aligns with Elon Musk's anti-regulation stance and traditional conservative skepticism toward tech moderation, promising fewer constraints on AI development. While this hands-off stance may accelerate innovation, it risks amplifying unchecked uses and biases in AI, raising concerns about potential harm to democracy and civil rights. Big Tech may face intensified scrutiny on issues like antitrust and Section 230 reform, though Trump might avoid actions that could impact his own platform, Truth Social. Additionally, although Trump once supported a TikTok ban, he may now oppose it, while privacy legislation remains uncertain, with a possible push for a federal standard from pro-business advocates. Experts remain divided on AI's future, with some seeing it as a force for progress, while others worry it could undermine democratic values if left unregulated in the global race with China.
š° AI News and Trends
AI Startup Perplexity to Triple Valuation to $9 Billion in New Funding Round (WSJ)
Anthropicās Haiku 3.5 surprises experts with an āintelligenceā price increase (ARS)
Nvidia Rides AI Wave to Pass Apple as Worldās Largest Company (Bloomberg)
OpenAI probes for-profit shift (NYP)
CoreWeave picks Morgan Stanley, Goldman, JPMorgan for IPO (YF)
š Other Tech news
Bitcoin Surges to Record as Crypto Investors Cheer Trump Win (NYT)
Apple warns investors future products may never be as profitable as iPhone (FT)
BYD Added A Tesla-Worth Of Production Capacity Over The Past 3 Months ā¦ With More To Come (CleanTechnica)
Global Disparities of Cancer and Its Projected Burden in 2050 (JN)
Japanese Scientists Bet on an Ancient Material for Their New Satellite: Wood (NYT)
EVs close to solidifying 10% market share amid continued sales growth (ETB)
Reply